Divya Jain | Pharmacology Award | Women Researcher Award

Posted on by ScienceFather

Dr. Divya Jain | Pharmacology Award | Women Researcher Award

Dr. Divya Jain, Uttaranchal University, India

Dr. Divya Jain is an accomplished microbiologist, holding a Ph.D. in Microbiology from Banasthali Vidyapith, Rajasthan (2023), an M.Sc. in Microbiology from Graphic Era University, Dehradun (2018), and a B.Sc. in Biotechnology from Banasthali Vidyapith (2016). She currently serves as an Assistant Professor at Uttaranchal University, Dehradun, bringing extensive expertise in microbiology to the Department of Microbiology. Her previous roles include an Associate Research Fellow at the Integrative Centre for Research & Innovation in Biology in Chandigarh. Dr. Jain also completed a notable internship in content and academic writing with The Applied Biology & Chemistry Journal. 📚🔬✨

Publication profile

Orcid

Google Scholar

🎓 Education

Dr. Divya Jain holds a Ph.D. in Microbiology from Banasthali Vidyapith, Rajasthan (2023), an M.Sc. in Microbiology from Graphic Era University, Dehradun (2018), and a B.Sc. in Biotechnology from Banasthali Vidyapith (2016). She completed her high school education in PCB from S.D.R.R Public School, Shamli (2013). 📘🔬

🏢 Work Experience

Currently an Assistant Professor at Uttaranchal University, Dehradun, Dr. Jain also served as an Associate Research Fellow at the Integrative Centre for Research & Innovation in Biology, Chandigarh. 📚🔬

🏅 Certificates and Awards

Dr. Jain has earned several accolades, including the Innovative Article Award and the Excellence in Research Award. She has also completed certificate courses in microbiology, forensic science, and RJ-Ing. 🏆📜

 

Research Focus 🔬🌍

Dr. Divya Jain’s research is primarily focused on microbiology, environmental science, and pharmacology. Her work includes studying microbial pollution, particularly coliform bacteria, and their environmental impact. She has also contributed significantly to sustainable agriculture through research on plant growth-promoting microorganisms and mycorrhiza. Dr. Jain explores the pharmacological applications of natural compounds, such as propolis and medicinal plants, for cancer therapy and liver protection. Her research extends to evaluating potential inhibitors for SARS-CoV-2 and other viral infections, emphasizing bioactive compounds from natural sources. Her multifaceted research underscores her dedication to addressing critical global health and environmental challenges. 🌱🧬🧪

 

Publication Top Notes

  • “Microbial pollution of water with special reference to coliform bacteria and their nexus with environment” 🌊🦠 (110 citations, 2021)
    S Some, R Mondal, D Mitra, D Jain, D Verma, S Das
    Energy Nexus 1, 100008
  • “Role of mycorrhiza and its associated bacteria on plant growth promotion and nutrient management in sustainable agriculture” 🌱🔬 (90 citations, 2020)
    D Mitra, N Uniyal, P Panneerselvam, A Senapati, AN Ganeshamurthy
    International Journal of Life Sciences and Applied Sciences 1 (1), 1-1
  • “Propolis: An update on its chemistry and pharmacological applications” 🍯⚗️ (73 citations, 2022)
    R Hossain, C Quispe, RA Khan, ASM Saikat, P Ray, D Ongalbek, …
    Chinese medicine 17 (1), 100
  • “Tobacco Smoking and Liver Cancer Risk: Potential Avenues for Carcinogenesis” 🚬🔬 (53 citations, 2021)
    D Jain, P Chaudhary, N Varshney, KS Bin Razzak, D Verma, …
    Journal of Oncology 2021 (1), 5905357
  • “Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PLpro and Mpro/3CLpro: molecular docking and simulation studies of three pertinent medicinal plant natural components” 🧬🌿 (44 citations, 2021)
    D Verma, D Mitra, M Paul, P Chaudhary, A Kamboj, H Thatoi, P Janmeda, …
    Current Research in Pharmacology and Drug Discovery 2, 100038
  • “Biosynthesis of secondary metabolites based on the regulation of microRNAs” 🧬🧪 (33 citations, 2022)
    R Hossain, C Quispe, ASM Saikat, D Jain, A Habib, P Janmeda, MT Islam, …
    BioMed Research International 2022 (1), 9349897
  • “Hepatoprotective activity of medicinal plants: A mini review” 🌿🛡️ (29 citations, 2020)
    D Jain, P Chaudhary, A Kotnala, R Hossain, K Bisht, MN Hossain
    Journal of Medicinal Plants Studies 8 (5), 183-188
  • “Quercetin and/or Ascorbic Acid Modulatory Effect on Phenobarbital-Induced Sleeping Mice Possibly through GABAA and GABAB Receptor Interaction Pathway” 💤🍊 (25 citations, 2021)
    R Hossain, K Al-Khafaji, RA Khan, C Sarkar, MS Islam, D Dey, D Jain, …
    Pharmaceuticals 14 (8), 721
  • “Anticancer effects of acteoside: Mechanistic insights and therapeutic status” 🧬🎗️ (22 citations, 2022)
    RA Khan, R Hossain, P Roy, D Jain, ASM Saikat, APR Shuvo, M Akram, …
    European Journal of Pharmacology 916, 174699
  • “Carcinogenic effects of N-nitroso compounds in environment” 🚫🦠 (22 citations, 2020)
    D Jain, P Chaudhary, N Varshney, P Janmeda
    Environment Conservation Journal 21 (3), 25-41

Patricia Rijo |Pharmacology, Toxicology | Best Researcher Award

Posted on by ScienceFather

Assoc Prof Dr. Patricia Rijo |Pharmacology, Toxicology | Best Researcher Award

Assoc Prof Dr, Patricia Rijo, Universidade Lusófona, Portugal

Assoc Prof Dr. Patricia Rijo is a distinguished academic at Universidade Lusófona in Portugal. With expertise in [mention her field or area of specialization], Dr. Rijo has contributed significantly to [mention any notable contributions or achievements, such as research, publications, or projects]. Her dedication to [mention any relevant causes or academic interests] underscores her commitment to advancing knowledge in her field. Dr. Rijo’s academic leadership and mentorship inspire both colleagues and students alike at Universidade Lusófona.

Publication profile

Scopus

Education

PhD in Pharmacy (specialty in Medicinal Chemistry and Therapeutics) with Distinction, Faculdade de Farmácia da Universidade de Lisboa, 2003.,Master’s Degree (MSc) in Medicinal Chemistry, Faculdade de Farmácia da Universidade de Lisboa, 2003.,Bachelor’s Degree in Chemistry, Faculdade de Ciências da Universidade de Lisboa, 1999.

Professional Experience

Dr. Hyunsook Lee has had a distinguished professional career in academia and research 👩‍🔬. She began as a Research Scientist at Mogam Biotech Research Institute in Korea (1992. Mar – 1994. May) 🔬 and was promoted to Senior Research Scientist (1994. May – 1996. Aug) 🧬. She then transitioned to academia as a Research Assistant Professor at Ewha Womans University (2002. Sept – 2003) 🧪. In 2004, she joined the Dept. of Biological Sciences at Seoul National University (SNU) as an Assistant Professor 📚, advancing to Associate Professor in 2008 and earning early tenure in 2010 🌟. By 2012, she became a full Professor at SNU 🌍. Dr. Lee has also served in several key administrative roles, including Vice Dean of Planning for the College of Natural Sciences (2015 July – 2017 June) 📅, and Dean for Research Affairs at SNU (2021. Feb – 2023. Feb) 🎓. She has been the Head of the AI-Bio Research Center since 2023 🧠🔬 and co-founded Next & Bio in 2019, which later merged with Kolmar Holdings in 2022 💼. Her visiting scientist positions include stints at the Dana Farber Cancer Institute (2010. Aug – 2011. July) 🧬 and Samsung Advanced Institute of Technology (2020. Aug – 2021. Feb) 🏥.

Academic Positions:

Associate Professor at Universidade Lusófona de Humanidades e Tecnologias (ULHT), since June 2020.,Assistant Professor at ULHT (2011-2020).,Coordinator Professor at Escola Superior de Ciências da Saúde (2011-2016).,Assistant at ULHT (2005-2010).,Invited Assistant Professor at Escola Superior de Saúde Ribeiro Sanches (2002-2011).,Monitor at Faculdade de Farmácia da Universidade de Lisboa (2001-2005).

Awards and Honors:

Egon Stahl-Award in Bronze from Society for Medicinal Plant and Natural Product Research (2022).,Various awards for scientific presentations and research contributions.

Additional Skills and Activities:

  • Languages: Proficiency in Portuguese (C2), English (B2), Spanish (B1), French (A2).
  • Supervision: Supervised numerous PhD and Master’s students.
  • Project Leadership: Participation and leadership in multiple research projects.

Publications:

  • Anticancer diterpenes of African natural products: Mechanistic pathways and preclinical developments
    • Authors: Bangay, G., Brauning, F.Z., Rosatella, A., Efferth, T., Rijo, P.
    • Journal: Phytomedicine, 2024, 129, 155634
    • Abstract: This article likely discusses the mechanistic pathways through which diterpenes from African natural products exhibit anticancer properties, as well as their development in preclinical studies.
  • Glycyrrhizic Acid Nanoparticles Subside the Activity of Methicillin-Resistant Staphylococcus aureus by Suppressing PBP2a
    • Authors: Rijo, P., Abuamara, T.M.M., Ali Lashin, L.S., Abd El Maksoud, A.I., Hassan, A.
    • Journal: Pharmaceuticals, 2024, 17(5), 589
    • Abstract: This article likely explores the use of glycyrrhizic acid nanoparticles to combat methicillin-resistant Staphylococcus aureus (MRSA) by targeting the penicillin-binding protein PBP2a.
  • Halimane Derivatives from Plectranthus ornatus Codd. as Novel Anti-cancer Agents
    • Authors: Bangay, G., Brauning, F.Z., Kowalczyk, T., Sitarek, P., Rijo, P.
    • Journal: Biomedicine and Pharmacotherapy, 2024, 174, 116516
    • Abstract: This article likely investigates the anticancer potential of halimane derivatives from Plectranthus ornatus.
  • Solving the antibacterial resistance in Europe: The multipronged approach of the COST Action CA21145 EURESTOP
    • Authors: Seguin-Devaux, C., Mestrovic, T., Arts, J.J., Rijo, P., Mori, M.
    • Journal: Drug Resistance Updates, 2024, 74, 101069
    • Abstract: This editorial likely outlines the efforts and strategies of the COST Action CA21145 EURESTOP in addressing antibacterial resistance in Europe.
  • Biological Activity of 6,7-Dehydroxyroyleanone and Derivatives Obtained from Plectranthus aliciae (Codd) A.J.Paton
    • Authors: Filipe, M.S., Domínguez-Martín, E.M., Pires, T.C.S.P., Barros, L., Rijo, P.
    • Journal: ACS Omega, 2024, 9(16), pp. 18113–18118
    • Abstract: This article likely details the biological activities of 6,7-dehydroxyroyleanone and its derivatives sourced from Plectranthus aliciae.
  • Exploring the Anticancer Potential of Semisynthetic Derivatives of 7α-Acetoxy-6β-hydroxyroyleanone from Plectranthus sp.: An In Silico Approach
    • Authors: Merecz-Sadowska, A., Isca, V.M.S., Sitarek, P., Rijo, P., Zajdel, R.
    • Journal: International Journal of Molecular Sciences, 2024, 25(8)
    • Abstract: This article likely explores the anticancer potential of semisynthetic derivatives of a specific compound from Plectranthus species using computational methods.
  • Anticancer Effects of Abietane Diterpene 7α-Acetoxy-6β-hydroxyroyleanone from Plectranthus grandidentatus and Its Semi-Synthetic Analogs: An In Silico Computational Approach
    • Authors: Isca, V.M.S., Sitarek, P., Merecz-Sadowska, A., Rijo, P., Kowalczyk, T.
    • Journal: Molecules, 2024, 29(8), 1807
    • Abstract: This article likely investigates the anticancer effects of abietane diterpene and its analogs from Plectranthus grandidentatus using computational techniques.
  • Antibiotic Coordination Frameworks against Antibiotic Resistance: How to Involve Students through Experimental Practices in the Search for Solutions to Public Health Problems
    • Authors: Domínguez-Martín, E.M., Ntungwe, E., Isca, V.M.S., André, V., Rijo, P.
    • Journal: Journal of Chemical Education, 2024, 101(5), pp. 2045–2051
    • Abstract: This article likely discusses educational strategies to involve students in experimental practices to address antibiotic resistance.
  • The Precious Potential of the Sacred Tree Chamaecyparis obtusa (Siebold & Zucc.) Endl. as a Source of Secondary Metabolites with Broad Biological Applications
    • Authors: Górski, K.M., Kowalczyk, T., Picot, L., Ghorbanpour, M., Sitarek, P.
    • Journal: International Journal of Molecular Sciences, 2024, 25(5), 2723
    • Abstract: This review likely highlights the various biological applications of secondary metabolites derived from Chamaecyparis obtusa.
  • Enhancement of Vitamin C’s Protective Effect against Thimerosal-Induced Neurotoxicity in the Cerebral Cortex of Wistar Albino Rats: An In Vivo and Computational Study
    • Authors: Hassan, A., Mohsen, R., Rezk, A., Abd El Maksoud, A.I., Mohamed, A.F.
    • Journal: ACS Omega, 2024, 9(8), pp. 8973–8984
    • Abstract: This article likely explores the neuroprotective effects of vitamin C against thimerosal-induced toxicity using both in vivo and computational methods.

Nagavendra Kommineni | Pharmacology Award | Best Researcher Award

Posted on by ScienceFather

Dr. Nagavendra Kommineni | Pharmacology Award | Best Researcher Award

Dr. Nagavendra Kommineni, Center for Biomedical Research, Population Council, United States

Dr. Nagavendra Kommineni, Ph.D., is a pharmaceutical scientist specializing in formulation development 🧪. With a background from NIPER-Hyderabad, India, he has expertise in designing innovative drug formulations, particularly in topical and transdermal delivery systems 🩺. His work spans nanoparticle-based platforms and sterile manufacturing processes for injectables. Currently a Postdoctoral Research Fellow in New York, he focuses on translational formulations for sexual and reproductive health, including freeze-dried protein formulations and fast-dissolving tablets 🌱. Dr. Kommineni is adept in analytical techniques and actively contributes to GLP and GMP manufacturing standards.

 

Publication Profile

Google Scholar

Education

Dr. Nagavendra Kommineni holds a Ph.D. in Pharmaceutical Sciences from NIPER-Hyderabad, India (2015-2019). He also earned an M.S (Pharm) in Pharmaceutical Sciences (2012-2014) and a Bachelor of Pharmacy degree from Bapatla College of Pharmacy, India (2008-2012).

Work Experience 🏥

As a Postdoctoral Research Fellow in New York, he pioneers translational formulations for sexual and reproductive health, overseeing formulation development, GLP toxicity studies, and GMP manufacturing. He leads projects on freeze-dried protein formulations and fast-dissolving tablets for HIV and contraception.

 

Research Focus

Dr. Nagavendra Kommineni’s research primarily focuses on advanced drug delivery systems 🚀, particularly liposomal formulations, nanocarriers, and depot microspheres for targeted therapy. He explores the potential of exosomes and dendrimers in drug delivery, aiming to enhance therapeutic efficacy while minimizing side effects 🎯. His investigations extend to the development of novel formulations for cancer therapy, psoriasis treatment, and overcoming drug resistance in diseases like breast cancer. Through his work, Dr. Kommineni contributes significantly to the advancement of pharmaceutical science, with a particular emphasis on improving patient outcomes through innovative delivery strategies.

 

Publication Top Notes

📚 Liposomal formulations in clinical use: an updated review 🔍 Cited by: 1953 📅 Year: 2017

📚 Amorphous solid dispersions: An update for preparation, characterization, mechanism on bioavailability, stability, regulatory considerations and marketed products 🔍 Cited by: 228 📅 Year: 2020

📚 Exosomes as naturally occurring vehicles for delivery of biopharmaceuticals: insights from drug delivery to clinical perspectives🔍 Cited by: 99 📅 Year: 2021

📚 PLGA/PLA-based long-acting injectable depot microspheres in clinical use: production and characterization overview for protein/peptide delivery 🔍 Cited by: 94 📅 Year: 2021

📚 Cabazitaxel and silibinin co-encapsulated cationic liposomes for CD44 targeted delivery: A new insight into nanomedicine based combinational chemotherapy for prostate cancer🔍 Cited by: 94 📅 Year: 2019

📚 Chitosan: A potential biopolymer in drug delivery and biomedical applications

📚 Lignin: drug/gene delivery and tissue engineering applications

📚 Exploring the potential of nanotherapeutics in targeting tumor microenvironment for cancer therapy

📚 Microneedle-based natural polysaccharide for drug delivery systems (DDS): progress and challenges

📚 Dithranol-loaded nanostructured lipid carrier-based gel ameliorate psoriasis in imiquimod-induced mice psoriatic plaque model

Anand Kumar | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Mr. Anand Kumar | Pharmaceutical Science | Best Researcher Award

Mr. Anand Kumar, Babasaheb Bhimrao Ambedkar University Lucknow, India

🎓 Dr. Anand Kumar is a dedicated researcher and educator with a profound academic background. He holds a Ph.D. in Pharmaceutical Sciences, specializing in areas like Cancer Biology, Muscle Biology, and Sarcopenia. An alumnus of prestigious institutions such as Babasaheb Bhimrao Ambedkar University and Chhatrapti Shahu Ji Maharaj University, Dr. AnandKumar has been honored with fellowships from Indian Council of Medical Research and University Grants Commission. His commitment to advancing pharmaceutical knowledge is underscored by his multiple qualifications and extensive research experience. With a passion for understanding and combating diseases, he represents a beacon of excellence in the field. 🏅

Publication Profile:

Orcid

Google Scholar

Education Qualifications:

🎓 Dr. AnandKumar’s educational journey is marked by a series of impressive accomplishments and a steadfast pursuit of excellence in pharmaceutical sciences. His academic odyssey began with an Intermediate degree in Physics, Chemistry, and Maths from the UP Board, where he attained a commendable first-class score. Venturing further into the realm of pharmacy, he obtained a D. Pharm from Sarojini Naidu Medical College, Agra, demonstrating his early dedication to the field. Undeterred by challenges, he pursued a B. Pharm from Chhatrapti Shahu Ji Maharaj University, Kanpur, and later, an M. Pharm in Pharmacology from Babasaheb Bhimrao Ambedkar University, Lucknow, where he consistently achieved first-class distinctions.His academic journey culminated in a significant milestone with a Ph.D. in Pharmaceutical Sciences from the same institution, where his thesis was submitted in July 2023. Dr. AnandKumar’s relentless pursuit of knowledge and his commitment to academic excellence are evident in his consistent academic achievements. Through his rigorous academic training, he has honed his expertise in areas such as pharmacology and pharmaceutical sciences, paving the way for impactful contributions to the field. Dr. AnandKumar’s educational trajectory exemplifies resilience, dedication, and a profound passion for advancing pharmaceutical research and practice. 🌟

Honors, Recognition, and Awards:

🏅 Dr. AnandKumar’s contributions to pharmaceutical research have been recognized through prestigious honors and awards. In 2022, he was bestowed with the Indian Council of Medical Research (ICMR) Senior Research Fellowship (SRF) by the Ministry of Health and Family Welfare, Government of India, acknowledging his exceptional research prowess. Prior to this, he received the PGSPROF Fellowship from the University Grants Commission (UGC) between 2016 and 2018, further affirming his dedication to academic excellence. Additionally, Dr. AnandKumar’s exemplary performance is underscored by his remarkable achievement of qualifying the Graduate Pharmacy Aptitude Test (GPAT) five times between 2017 and 2023, highlighting his commitment to continuous learning and proficiency in pharmaceutical sciences. 🌟

Professional Experience:

👨‍🏫 Dr. AnandKumar’s professional journey includes both teaching and research experiences, shaping him into a well-rounded pharmaceutical scientist. His teaching tenure spans six months, during which he imparted knowledge and mentored students in various aspects of pharmacy. Complementing his role in academia, Dr. AnandKumar has amassed valuable research experience in diverse domains. Through his engagement in research, he has delved into intricate subjects such as Cancer Biology, Muscle Biology, and Sarcopenia, contributing significantly to the advancement of pharmaceutical sciences. His dual expertise in teaching and research reflects his commitment to academic excellence and his passion for pushing the boundaries of scientific inquiry. 📚🔬

Research Focus:

🔬 Dr. Anand Kumar’s research focus encompasses a broad spectrum of pharmaceutical sciences, with a particular emphasis on combating various aspects of muscle biology-related disorders. His work delves into elucidating mechanisms underlying skeletal muscle wasting conditions such as sarcopenia, diabetic muscle atrophy, and muscle damage induced by diverse factors. Through innovative approaches including pharmacological interventions and targeted drug delivery systems, he aims to mitigate muscle wasting and associated inflammatory responses. Dr. AnandKumar’s multidisciplinary research endeavors, as evidenced by his publications, contribute significantly to understanding and addressing the complexities of muscle-related pathologies, paving the way for novel therapeutic strategies in the field. 🌟

Publication Top Notes:

Novel synergistic approach: tazarotene-calcipotriol-loaded-PVA/PVP-nanofibers incorporated in hydrogel film for management and treatment of psoriasis

Azilsartan Ameliorates Skeletal Muscle Wasting in High Fat Diet (HFD)-induced Sarcopenic Obesity in Rats via Activating Akt Signalling Pathway

Salbutamol ameliorates skeletal muscle wasting and inflammatory markers in streptozotocin (STZ)-induced diabetic rats

Vinpocetine mitigates DMH-induce pre-neoplastic colon damage in rats through inhibition of pro-inflammatory cytokines

Salbutamol Attenuates Diabetic Skeletal Muscle Atrophy by Reducing Oxidative Stress, Myostatin/GDF-8, and Pro-Inflammatory Cytokines in Rats

Atenolol Ameliorates Skeletal Muscle Atrophy and Oxidative Stress Induced by Cast Immobilization in Rats

Evaluation Of Azilsartan Transdermal Hydrogel In Volumetric Muscle Loss Injury In A Rat Model

Investigating the Role of Angiotensin Receptor Blockers (ARBs) In High Fat Diet-Induced Sarcopenic Rats Associated Muscle Wasting

Pentapeptide cRGDfK-Surface Engineered Nanostructured Lipid Carriers as an Efficient Tool for Targeted Delivery of Tyrosine Kinase Inhibitor for Battling Hepatocellular Carcinoma